CONSULTING AGREEMENT TERM EXTENSIONConsulting Agreement Term Extension • March 31st, 2023 • AIM ImmunoTech Inc. • Biological products, (no disgnostic substances)
The Consulting Agreement (the “Agreement”) has been made effective as of March 1, 2022, the date fully executed by both parties (the “Effective Date”), by and between AIM ImmunoTech Inc., a Delaware corporation, with its principal place of business being 2117 SW Highway 484, Ocala FL 34473 (the “Company”) and Foresite Advisors, LLC, a Pennsylvania limited liability corporation, with its principal place of business being ————Philadelphia, PA 19118 (“Foresite”).
EXPLANATORY NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. INVESTIGATOR INITIATED STUDY SUPPORT AGREEMENT For clinical trials...Support Agreement • March 31st, 2023 • AIM ImmunoTech Inc. • Biological products, (no disgnostic substances)
REGARDING Combining anti-PD-L1 immune checkpoint inhibitor durvalumab with TLR-3 agonist rintatolimod in patients with metastatic pancreatic ductal adenocarcinoma for therapy efficacy. (DURIPANC) Study. Protocol number: EudraCT:2022-003780-23, NL83224.078.22
DATED December 5th, 2022 STERLING PHARMA SOLUTIONS LIMITED and AIM IMMUNOTECH INC. MASTER SERVICES AGREEMENTMaster Services Agreement • March 31st, 2023 • AIM ImmunoTech Inc. • Biological products, (no disgnostic substances)
NOW, THEREFORE, BE IT RESOLVED, that for and in consideration of the mutual promises and covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:
EXPLANATORY NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. CO-ORDINATION AGREEMENT (“Agreement”)Co-Ordination Agreement • March 31st, 2023 • AIM ImmunoTech Inc. • Biological products, (no disgnostic substances)
● AIM ImmunoTech is an immune-pharma company focused on the research and development of therapeutics to treat multiple types of cancer. AIM ImmunoTech’s flagship product is Rintatolimod.
